Perfection of Nonpossessory Security Interests Under Revised Aritcle 9: Consequences of the Practical and Conceptual Incompatibility of US and English Secured Transactions Law

Article 9 of the Uniform Commercial Code ( UCC ), governing secured transactions, was recently revised, changing the way in which nonpossessory security interests are perfected.\u27 All fifty states have approved the revision, which became effective in most states as of July 1, 2001. The changes affect foreign debtors differently depending upon whether their laws are compatible with revised Article 9. Given the sizeable amount of money that US banks loan to UK banks and corporations, English secured transactions law is particularly significant. This paper focuses on the incompatibility of English law with revised Article 9. The paper first examines the basics of where to file financing statements in order to perfect nonpossessory security interests under revised Article 9, contrasting the simplicity of determining the location of US debtors with the complexity of determining the location of foreign debtors. The paper then examines English law for compatibility with Article 9, because compatibility affects the method of determining the location of English debtors. Both practical incompatibility under current English law and possible conceptual incompatibility under future English law are considered. Finally, the paper highlights why filing must take place in the District of Columbia, notwithstanding the potential risks if a duplicate filing is not made in England

Effects of carbon dioxide on carnation growth, The

Includes bibliographical references (pages 51-56).August, 1961.In the past five years, much progress has been made in the control of greenhouse environment. With the advent of automation for heating and air conditioning, fertilizer injection systems, automatic watering systems and increased light due to various types of greenhouse construction, near optimum relationships have resulted within the environmental complex and have led to increased production and quality. It is quite possible that further increases in plant growth may be obtained by atmospheric fertilization with carbon dioxide, thus bringing into equipoise the environmental complex. Carbon dioxide is one of the least considered factors in plant growth by most researchers, although some realize it’s very definite importance to the environmental complex. Several investigators have increased the carbon dioxide concentration of the atmosphere surrounding plants with positive results of increased plant growth. Other investigators have reported no increase in dry matter production from carbon dioxide fertilization. A carbon dioxide analyzing system consisting of a Beckman infrared analyzer and amplifier, a recorder, and a multiple port selector valve was installed in the research greenhouses. It was used to record continuously carbon dioxide concentrations throughout the greenhouse range and help maintain established levels of carbon dioxide in controlled chambers. Carbon dioxide concentrations in carnation and rose greenhouses dropped below 225 ppm on days of cold cloudy weather when there was no ventilation. Ventilating on warmer days increased the carbon dioxide concentration to near that of outside atmospheric levels. Four chambers of polyvinyl plastic were cooled by refrigeration and the air continuously recirculated. Each chamber had a constant temperature of 65° F and an air flow of 130 FPM across the plants during daylight hours. At night the temperature dropped to approximately 52° F when the doors were opened and the recirculating air system turned off. Light levels were dependent upon climatic influences. Carbon dioxide concentrations were controlled as closely as possible during daylight hours at 200, 350, and 550 ppm. Rooted cuttings of the carnation variety Red Gayety were planted in the chambers on May 28, 1960 and grown until the termination date, June 2, 1961. The following responses were observed as carbon dioxide concentrations increased: a. The yields in the 550 ppm were 38 percent and in the 350 ppm, 30 percent more than the yield in the 200 ppm concentration. b. The first and second crops in the 350 and 550 ppm levels flowered 2 weeks ahead of the 200 ppm level. c. The average stem length in the 550 ppm level was 2 inches shorter and in the 350 ppm level, 1 inch shorter than the stems produced in the 200 ppm level. d. Approximately equal fresh and dry weights were produced in all levels. e. The percentage of dry matter increased approximately 0.5 percent in the 350 ppm level and 1 percent in the 550 level over the 200 ppm concentration. f. The second internode decreased and the fifth increased in length as carbon dioxide concentrations increased. g. There were similar amounts of sucrose and fructose in young vegetative shoots harvested in all 3 concentrations. h. Flowers harvested from all 3 carbon dioxide concentrations had a keeping life of approximately 10 days

Gaslighting Female Leadership: All Gas, No Brakes!

In this study, we asked: Does female leadership style safeguard Black female leaders against gaslighting? Between September 2023 and December 2023, we read case studies, reviewed numerous government publications and documents, and read peer-reviewed published articles and scholarly books retrieved from Google Scholar and library databases. Burn’s (1978) definition of a transformational leader is how we, too, define a leader. One definition of gaslighting stood out, and we used that definition to operationalize our investigation (Duignan, 2023). We found that when female leaders are exposed to gaslighting, they are less likely to participate in workforce leadership initiatives. Gaslighting negatively impacts female leaders’ performance; nonetheless, a few female leadership styles safeguard female leaders from the drawbacks of gaslighting. We make four recommendations that will help Black female leaders avoid the pitfalls of gaslighting

Techno-economic evaluation of reducing shielding gas consumption in GMAW whilst maintaining weld quality

A new method of supplying shielding gases in an alternating manner has been developed to enhance the efficiency of conventional gas metal arc welding (GMAW). However, the available literature on this advanced joining process is very sparse and no cost evaluation has been reported to date. In simple terms, the new method involves discretely supplying two different shielding gases to the weld pool at predetermined frequencies which creates a dynamic action within the liquid pool. In order to assess the potential benefits of this new method from a technical and cost perspective, a comparison has been drawn between the standard shielding gas composition of Ar/20%CO2, which is commonly used in UK and European shipbuilding industries for carbon steels, and a range of four different frequencies alternating between Ar/20%CO2 and helium. The beneficial effects of supplying the weld shielding gases in an alternating manner were found to provide attractive benefits for the manufacturing community. For example, the present study showed that compared with conventional GMAW, a 17 per cent reduction in total welding cost was achieved in the case of the alternating gas method and savings associated with a reduction in the extent of post-weld straightening following plate distortion were also identified. Also, the mechanical properties of the alternating case highlighted some marginal improvements in strength and Charpy impact toughness which were attributed to a more refined weld microstructure

Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl

Background: A phase 3 randomized clinical trial was designed to test whether bardoxolone methyl, a nuclear factor erythroid-2–related factor 2 (Nrf2) activator, slows progression to end-stage renal disease in patients with stage 4 chronic kidney disease and type 2 diabetes mellitus. The trial was terminated because of an increase in heart failure in the bardoxolone methyl group; many of the events were clinically associated with fluid retention.<p></p> Methods and Results: We randomized 2,185 patients with type 2 diabetes mellitus (T2DM) and stage 4 chronic kidney disease (CKD) (estimated glomerular filtration rate 15 to <30 mL min−1 1.73 m−2) to once-daily bardoxolone methyl (20 mg) or placebo. We used classification and regression tree analysis to identify baseline factors predictive of heart failure or fluid overload events. Elevated baseline B-type natriuretic peptide and previous hospitalization for heart failure were identified as predictors of heart failure events; bardoxolone methyl increased the risk of heart failure by 60% in patients with these risk factors. For patients without these baseline characteristics, the risk for heart failure events among bardoxolone methyl– and placebo-treated patients was similar (2%). The same risk factors were also identified as predictors of fluid overload and appeared to be related to other serious adverse events.<p></p> Conclusions: Bardoxolone methyl contributed to events related to heart failure and/or fluid overload in a subpopulation of susceptible patients with an increased risk for heart failure at baseline. Careful selection of participants and vigilant monitoring of the study drug will be required in any future trials of bardoxolone methyl to mitigate the risk of heart failure and other serious adverse events.<p></p&gt

Using computer graphics to design Space Station Freedom viewing

Viewing requirements were identified early in the Space Station Freedom program for both direct viewing via windows and indirect viewing via cameras and closed-circuit television (CCTV). These requirements reside in NASA Program Definition and Requirements Document (PDRD), Section 3: Space Station Systems Requirements. Currently, analyses are addressing the feasibility of direct and indirect viewing. The goal of these analyses is to determine the optimum locations for the windows, cameras, and CCTV's in order to meet established requirements, to adequately support space station assembly, and to operate on-board equipment. PLAID, a three-dimensional computer graphics program developed at NASA JSC, was selected for use as the major tool in these analyses. PLAID provides the capability to simulate the assembly of the station as well as to examine operations as the station evolves. This program has been used successfully as a tool to analyze general viewing conditions for many Space Shuttle elements and can be used for virtually all Space Station components. Additionally, PLAID provides the ability to integrate an anthropometric scale-modeled human (representing a crew member) with interior and exterior architecture

Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes:Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study

Background: Increases in measured inulin clearance, measured creatinine clearance, and estimated glomerular filtration rate (eGFR) have been observed with bardoxolone methyl in 7 studies enrolling approximately 2,600 patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). The largest of these studies was Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), a multinational, randomized, double-blind, placebo-controlled phase 3 trial which enrolled patients with T2D and CKD stage 4. The BEACON trial was terminated after preliminary analyses showed that patients randomized to bardoxolone methyl experienced significantly higher rates of heart failure events. We performed post-hoc analyses to characterize changes in kidney func-tion induced by bardoxolone methyl. Methods: Patients in -BEACON (n = 2,185) were randomized 1: 1 to receive oncedaily bardoxolone methyl (20 mg) or placebo. We compared the effects of bardoxolone methyl and placebo on a post-hoc composite renal endpoint consisting of = 30% decline from baseline in eGFR, eGFR <15 mL/min/1.73 m2, and end-stage renal disease (ESRD) events (provision of dialysis or kidney transplantation). Results: Consistent with prior studies, patients randomized to bardoxolone methyl experienced mean increases in eGFR that were sustained through study week 48. Moreover, increases in eGFR from baseline were sustained 4 weeks after cessation of treatment. Patients randomized to bardoxolone methyl were significantly less likely to experience the composite renal endpoint (hazards ratio 0.48 [95% CI 0.36-0.64]; p <0.0001). Conclusions: Bardoxolone methyl preserves kidney function and may delay the onset of ESRD in patients with T2D and stage 4 CKD. (C) 2018 The Author(s) Published by S. Karger AG, Base

Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease

AimsObesity is associated with progression of chronic kidney disease (CKD). Treatment with bardoxolone methyl in a multinational phase 3 trial, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), resulted in increases in estimated glomerular filtration rate (eGFR) with concurrent reductions in body weight. We performed post-hoc analyses to further characterize reductions in body weight with bardoxolone methyl.MethodsEligible patients with type 2 diabetes (T2DM) and CKD stage 4 (eGFR 15 to &lt;30 mL/min/1.73 m2) were randomized 1:1 to receive once-daily oral dose of bardoxolone methyl (20 mg) or placebo.ResultsBEACON enrolled 2185 patients. Patients randomized to bardoxolone methyl experienced significant reductions in body weight from baseline relative to patients randomized to placebo (-5.7 kg; 95% CI: -6.0 to -5.3 kg; p &lt; 0.001). In patients randomized to bardoxolone methyl, rate and magnitude of body weight loss were proportional to baseline BMI. Bardoxolone methyl resulted in significant reductions in waist circumference and improved glycemic control.ConclusionsBardoxolone methyl resulted in significant weight loss in a generally obese patient population with T2DM and stage 4 CKD, with the magnitude and rate dependent on baseline BMI

Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia

OBJECTIVE: Previous studies have demonstrated that suppression of Nrf2 in Friedreich ataxia tissues contributes to excess oxidative stress, mitochondrial dysfunction, and reduced ATP production. Omaveloxolone, an Nrf2 activator and NF-kB suppressor, targets dysfunctional inflammatory, metabolic, and bioenergetic pathways. The dose-ranging portion of this Phase 2 study assessed the safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia patients (NCT02255435). METHODS: Sixty-nine Friedreich ataxia patients were randomized 3:1 to either omaveloxolone or placebo administered once daily for 12 weeks. Patients were randomized in cohorts of eight patients, at dose levels of 2.5–300 mg/day. RESULTS: Omaveloxolone was well tolerated, and adverse events were generally mild. Optimal pharmacodynamic changes (noted by changes in ferritin and GGT) were observed at doses of 80 and 160 mg/day. No significant changes were observed in the primary outcome, peak work load in maximal exercise testing (0.9 ± 2.9 W, placebo corrected). At the 160 mg/day dose, omaveloxolone improved the secondary outcome of the mFARS by 3.8 points versus baseline (P = 0.0001) and by 2.3 points versus placebo (P = 0.06). Omaveloxolone produced greater improvements in mFARS in patients that did not have musculoskeletal foot deformity (pes cavus). In patients without this foot deformity, omaveloxolone improved mFARS by 6.0 points from baseline (P < 0.0001) and by 4.4 points versus placebo (P = 0.01) at the 160 mg/day. INTERPRETATION: Treatment of Friedreich ataxia patients with omaveloxolone at the optimal dose level of 160 mg/day appears to improve neurological function. Therefore, omaveloxolone treatment is being examined in greater detail at 150 mg/day for Friedreich ataxia